NO20070174L - Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi - Google Patents

Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi

Info

Publication number
NO20070174L
NO20070174L NO20070174A NO20070174A NO20070174L NO 20070174 L NO20070174 L NO 20070174L NO 20070174 A NO20070174 A NO 20070174A NO 20070174 A NO20070174 A NO 20070174A NO 20070174 L NO20070174 L NO 20070174L
Authority
NO
Norway
Prior art keywords
insulin
preparations
control
prevention
methods
Prior art date
Application number
NO20070174A
Other languages
English (en)
Inventor
Daniel T Green
Robert R Henry
Original Assignee
Diobex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diobex Inc filed Critical Diobex Inc
Publication of NO20070174L publication Critical patent/NO20070174L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives farmasøytiske preparater omfattende både insulin og glukagon. Slike preparater kan administreres for å kontrollere og å behandle diabetes mens samtidig risikoen for insulinindusert hypoglykemi kan reduseres eller elimineres.
NO20070174A 2004-06-29 2007-01-10 Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi NO20070174L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58444904P 2004-06-29 2004-06-29
PCT/US2005/022812 WO2006004696A2 (en) 2004-06-29 2005-06-27 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (1)

Publication Number Publication Date
NO20070174L true NO20070174L (no) 2007-03-13

Family

ID=35783298

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070174A NO20070174L (no) 2004-06-29 2007-01-10 Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi

Country Status (11)

Country Link
EP (1) EP1778266A4 (no)
JP (1) JP2008505087A (no)
KR (1) KR20070029276A (no)
CN (1) CN101001638A (no)
AU (1) AU2005260025A1 (no)
CA (1) CA2571030A1 (no)
IL (1) IL180361A0 (no)
MX (1) MXPA06014970A (no)
NO (1) NO20070174L (no)
WO (1) WO2006004696A2 (no)
ZA (1) ZA200700708B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059762A1 (en) 2010-11-03 2012-05-10 Arecor Limited Novel composition comprising glucagon
WO2017040928A1 (en) * 2015-09-04 2017-03-09 Latitude Pharmaceuticals, Inc. Stabilized glucagon solutions
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
EP4233876A1 (en) * 2017-02-03 2023-08-30 Vanderbilt University Systems, compositions and methods for treating diabetes
CN110913888A (zh) * 2017-07-14 2020-03-24 Xeris药物公司 治疗先天性高胰岛素血症的方法
WO2019108640A1 (en) * 2017-11-28 2019-06-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods and kits for evaluating metabolism

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
EP1565437A1 (en) * 2002-11-18 2005-08-24 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
CN1732012A (zh) * 2002-12-27 2006-02-08 迪奥贝克斯公司 用于预防和控制胰岛素诱发的低血糖的组合物和方法

Also Published As

Publication number Publication date
KR20070029276A (ko) 2007-03-13
CA2571030A1 (en) 2006-01-12
AU2005260025A1 (en) 2006-01-12
IL180361A0 (en) 2007-06-03
WO2006004696A3 (en) 2006-10-26
JP2008505087A (ja) 2008-02-21
WO2006004696A2 (en) 2006-01-12
EP1778266A4 (en) 2009-09-09
CN101001638A (zh) 2007-07-18
ZA200700708B (en) 2009-03-25
EP1778266A2 (en) 2007-05-02
MXPA06014970A (es) 2007-03-07

Similar Documents

Publication Publication Date Title
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
NO20070174L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
NO20054534L (no) Leveringssystem for legemiddel og celleterapi
WO2009142772A3 (en) Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
ATE552031T1 (de) Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
Cao et al. The clinical application of linagliptin in Asians
MX2009007723A (es) Medicacion basada en exenatida y dalargina para el tratamiento de diabetes mellitus, su uso y modalidad de tratamiento.
Bader et al. Vildagliptin more effectively achieves a composite endpoint of HbA1c< 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment
CO2021013251A2 (es) Derivados de insulina sensibles a la glucosa
TNSN08144A1 (en) Kit for parenteral administration of medicaments
NO20075199L (no) Treatment or prevention of pruritus
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
EA201070557A1 (ru) Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов
MD20060037A (ro) Metodă de tratament al hepatitei virale acute C
Kulasekararaj et al. Phase 3 study of danicopan, an oral complement factor d inhibitor, as add-on therapy to a C5 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with clinically evident extravascular hemolysis
Cohn et al. San Antonio vasopressin in shock symposium report
Gadsby New treatments for type 2 diabetes—The DPP4 inhibitors
Mascitelli et al. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence
Xu et al. Acute efficacy of a novel anti-tissue factor pathway inhibitor antibody BAY 1093884 in hemophilia A mouse severe tail bleeding
Sanchez et al. Variceal bleeding and long-acting octreotide: a new addition to the armamentarium?
NO20075831L (no) Krystallinske faste og amorfe former av (-)- halofenat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application